lipoic acid synthetaseGenealiases: HGCLAS · HUSSY-01 · LAS · LIP1 · LS · PDHLD
Q-omics provides the consensus-scored LIAS profile across patient tissues and cancer cell-line models. LIAS expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LIAS is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, LIAS RNA expression shows 18,751 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where LIAS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIAS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIAS survival associations across molecular data types. LIAS RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIAS RNA expression–survival associations across cancer types. High LIAS expression shows unfavorable associations in KICH, but favorable associations in KIRC, MESO, COAD, BRCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LIAS RNA expression.
This table summarizes LIAS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LIAS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIAS shows lower tumor expression in THCA, BRCA, HNSC, UCEC and READ and higher tumor expression in LIHC. The THCA box plot shows higher LIAS RNA expression in normal versus tumor tissue (log2 FC = −0.430, t-test p < 0.001).
This table shows molecular features associated with LIAS in patient tissues and cancer cell lines. In patient samples, LIAS shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LIAS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
